FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Harrow moved its headquarters to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results